STARTUP PROFILE

BrainsWay

COUNTRY
Israel
FOUNDED
2003
CATEGORY
Neuromodulation
Developing non-invasive deep transcranial magnetic stimulation systems for the treatment of psychiatric and neurological disorders.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Public
MODALITY
TMS
FORM FACTOR
Headset/cap
INTERFACE DEPTH
Non-invasive
INDICATION
Psychiatry
TARGET USER
Clinicians
REGULATORY STAGE
FDA cleared (510k)
BrainsWay is the most broadly FDA-cleared deep TMS company, with distinct clearances across MDD, OCD, smoking cessation, and anxiety, plus a recent adolescent expansion, giving it the widest approved indication set of any TMS system on the market. As a publicly traded company with established clinical reimbursement pathways, it is best understood as an incumbent platform in non-invasive psychiatric neuromodulation rather than an emerging startup.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
13
Neurotech wants to challenge GLP-1s
27 October – 10 November 2026

BrainsWay launched a collaboration with Mindful Health Solutions covering access to Deep TMS, Neurolief’s at-home Proliv Rx, and physician education. No financial terms or system numbers were disclosed.

#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

BrainsWay reported that more than 118 million Americans now have insurance coverage for its Deep TMS treatment for OCD. Earlier this month, coverage for its accelerated depression protocol also surpassed 70 million people.

Articles featuring
BrainsWay